2022 Fiscal Year Final Research Report
Determination of disease characteristics of Castleman's disease and Rheumatoid arthritis using serum cytokine and chemokine patterns.
Project/Area Number |
20K10460
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 58020:Hygiene and public health-related: including laboratory approach
|
Research Institution | Louis Pasteur Center for Medical Research |
Principal Investigator |
Uno Kazuko 公益財団法人ルイ・パストゥール医学研究センター, IFN・生体防御研究室, 研究員(移行) (50211082)
|
Co-Investigator(Kenkyū-buntansha) |
吉崎 和幸 大阪大学, 産業科学研究所, 特任教授 (90144485)
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | IL-6 / トシリズマブ / サイトカイン / ケモカイン / PLS2解析 |
Outline of Final Research Achievements |
Rheumatoid arthritis, Castleman's disease, and COVID-19 can be effectively treated with Tocilizumab(TCZ), an antihuman IL-6 receptor antibody drug that inhibits the action of IL-6. The pathogenesis of all three disease are different: rheumatoid arthritis is an autoimmune disease, Castleman's disease is a lymphoproliferative disease, and COVID-19 is an infectious disease. We comprehensively measured cytokine/chemokines in the blood serum of patients before/after TCZ treatments and compared all three diseases with the serum of healthy subjects. By clarifying the cytokine/chemokine system affected by TCZ in each disease, the effect of treatment and changes in cytokine/chemokine dynamics, will reveal how IL-6 is involved in the clinical symptoms, and whether blocking IL-6 can result in significant improvements or the elimination of these symptoms.
|
Free Research Field |
免疫学
|
Academic Significance and Societal Importance of the Research Achievements |
リウマチとキャッスルマン病、COVID-19はIL-6の作用を抑制する抗ヒトIL-6受容体の抗体薬(TCZ:トシリズマブ)による治療が有効であるが、病因は全く異なる疾患である。各疾患のTCZ治療前後でのサイトカイン・ケモカインの動態を測定し、その変化を解析する事により、TCZの各疾患に対する作用を明らかにする。また、各疾患の特性にせまることが可能となる。
|